环状RNA circTCF25通过miR-103a-3p/miR-107调控CDK6的表达促进膀胱癌的增殖和迁移

该文旨在探讨环状RNA circTCF25对膀胱癌增殖和迁移的影响。采用RT-q PCR检测膀胱癌及癌旁组织中miR-103a-3p和miR-107的表达水平;采用Western blot和免疫组化检测膀胱癌细胞及膀胱癌和癌旁组织中CDK6的蛋白表达;将circTCF25过表达载体转染两种膀胱癌细胞后,采用RT-q PCR检测细胞中circTCF25以及miR-103a-3p和miR-107的表达水平;采用双荧光素酶报告基因实验验证circTCF25靶向结合miR-107及miR-107的靶基因CDK6;划痕实验检测细胞迁移能力;Edu实验检测细胞增殖能力。RT-q PCR结果表明,膀胱癌组织中miR-103a-3p和miR-107的表达明显低于癌旁组织。免疫组化和Western blot结果显示,膀胱癌组织中CDK6蛋白质水平明显高于癌旁组织。转染circTCF25过表达载体的细胞中,circTCF25的表达水平高于对照组。过表达circTCF25后,细胞中miR-103a-3p和miR-107的表达显著下降,CDK6的蛋白水平增加。双荧光素酶报告基因实验表明,circTCF25可以直接结合miR-107并降低其对靶基因CDK6的抑制。过表达circTCF25后,细胞迁移和增殖能力增强。该研究说明,环状RNA circTCF25可通过miR-103a-3p/miR-107调控CDK6的表达促进膀胱癌的增殖和迁移。     

下调脂肪酸合成酶表达对膀胱癌UMUC3细胞增殖、迁移及侵袭能力的影响*

目的: 研究脂肪酸合成酶(FASN)表达对膀胱癌UMUC3细胞增殖、迁移、侵袭的影响,探讨其内在可能机制。方法:免疫组化法检测30例膀胱癌和15例正常膀胱组织FASN蛋白的表达;用脂质体2000分别转染FASN siRNA和无义siRNA至UMUC3细胞,筛选、鉴定siFASN和siControl稳定的细胞,siFASN组细胞设为实验组,siControl组设为对照组;采用蛋白印迹法(Western blot)和实时荧光定量PCR(RT-PCR)法分别检测siFASN组和siControl组细胞FASN蛋白及mRNA的表达,MTT法检测siFASN组和siControl组细胞增殖情况,划痕试验、Transwell试验分别检测siFASN组和siControl组细胞迁移、侵袭能力。结果:FASN蛋白在膀胱癌组织中过表达,且与病理分期、分级密切相关(P＜0.05)。与siControl组相比,siFASN组细胞FASN mRNA及蛋白表达下调(P＜0.05),细胞增殖活力明显下降(P＜0.05),迁移能力明显下降(P＜0.05),穿膜细胞数量明显减少(P＜0.05)。结论:FASN过表达在膀胱癌发生、发展中发挥重要作用,下调FASN表达能抑制膀胱癌细胞的增殖、迁移、侵袭能力,抑制FASN表达有望成为一种新的膀胱癌治疗方法。     

尿路上皮癌胚抗原1（UCA1）在人膀胱癌组织及膀胱癌细胞株中特异表达

UCA1（urothelial carcinoma antigen 1）为自主研发的1个尿路上皮癌基因.应用 实时荧光定量PCR检测UCA1 mRNA在2种膀胱癌细胞系、11种非膀胱癌细胞系、18对膀胱 癌组织和配对癌旁正常膀胱组织中的表达,对表达差异进行统计学分析.结果显示, UCA1在2种膀胱癌细胞系中显著高表达,而在其他11种非膀胱癌细胞系中表达水平很低 或者不表达,二者表达差异达14~24 812倍,差异有统计学意义（P<0.001）;在18例膀 胱癌组织中,UCA1的平均表达水平是癌旁正常膀胱组织的12.4倍,表达差异有统计学意 义（P<0.001）. 实时荧光定量PCR使UCA1在膀胱癌细胞系及组织中的特异性高表达得以 量化.实验结果明确了UCA1作为潜在的肿瘤标记物在膀胱癌临床诊断中的意义,为定量 检测尿液UCA1表达并确定诊断膀胱癌的参考值打下基础.     

STAT3及下游基因Cyclin D1在膀胱癌中的表达及意义

目的 探讨STAT3及下游基因CyclinD1在膀胱癌中的表达及临床意义.为膀胱癌的基因治疗提供理论依据.方法 收集武汉大学人民医院病理科2004-2006年膀胱移行细胞癌存档蜡块50例,其中男性38例,女性12例,平均年龄50.3岁,另取5例癌旁组织做对照.标本均经HE染色,光镜观察诊断,按WHO病理分级标准,G1:30例,G2:15例,G3:5例;运用免疫组织化学染色方法检测STAT3和CyclinD1在以上各组中的表达.利用HPIAS-2000图像分析系统测定STAT3和CyclinD1在以上各组中表达的平均光密度和平均阳性面积率.结果 1.STAT3的表达:STAT3在膀胱移行细胞癌中呈高表达;STAT3在癌旁组织中呈低表达.膀胱移行细胞癌与癌旁组织比较,STAT3的表达差异有显著性(P＜0.05);2.CyclinD1的表达:CyclinD1在膀胱移行细胞癌中呈高表达;CyclinD1在癌旁组织中呈低表达.膀胱移行细胞癌与癌旁组织比较,CyclinD1的表达差异有显著性(P＜0.05).结论 1.STAT3可能参与了膀胱癌细胞的增殖分化、细胞周期等的调节;2.STAT3的活化促进了抗凋亡基因CyclinD1的表达;3.STAT3及其下游基因CyclinD1在膀胱癌的形成中起了一定作用.     

miR-302通过下调靶基因RAB22A抑制膀胱癌进展

目的:探讨miR-302通过靶向调控RAB22A影响膀胱癌进展的分子机制。方法:采用RT-qPCR检测miR-302在HTB1和RT112膀胱癌细胞系和膀胱内皮细胞系HBdNEC中的表达;以miRNA-NC、miR-302 mimic、miR-302 inhibitor转染细胞,并分为以下几组:NC+control si RNA、miR-302 inhibitor+control si RNA、miR-302 inhibitor+RAB22A si RNA、NC+vector、miR-302 mimic+vector或miR-302 mimic+RAB22A,再通过MTT实验分析膀胱癌细胞的增殖情况,细胞侵袭实验检测细胞侵袭情况,双荧光素酶报告载体检测分析miR-302靶基因,Western blot检测RAB22A在膀胱癌细胞中的表达。结果:HTB1和RT112细胞中miR-302的表达明显低于HBdNEC细胞(P0.05)。miR-302高表达抑制膀胱癌细胞的增殖和侵袭;miR-302低表达时,膀胱癌细胞的增殖和侵袭能力上升。生物信息学和双荧光素酶报告结果显示RAB22A为miR-302的靶基因。miR-302过表达后,细胞荧光素酶活性显著下降(P0.05),RAB22A表达下调(P0.05);miR-302表达沉默后,细胞荧光素酶活性显著上升(P0.05),RAB22A表达上调(P0.01)。拯救实验显示RAB22A表达沉默可逆转miR-302表达沉默时对膀胱癌细胞增殖和侵袭能力上调的影响;而RAB22A过表达可逆转miR-302过表达对膀胱癌细胞增殖和侵袭的抑制。结论:miR-302可通过抑制靶基因RAB22A的表达,抑制膀胱癌细胞的增殖及侵袭。     

TTK对膀胱癌细胞增殖、凋亡、侵袭及迁移的影响

该研究探讨了苏氨酸和酪氨酸激酶(threonine and tyrosine kinase,TTK)在膀胱癌中的表达情况及其在膀胱癌细胞增殖、凋亡、侵袭及迁移中的作用。采用qRT-PCR和免疫组织化学分别检测TTK mRNA和蛋白在癌旁正常组织、非肌层浸润性膀胱癌组织、肌层浸润性膀胱癌组织中的表达水平;将TTK过表达质粒、TTK敲除质粒借助脂质体分别稳定转染膀胱癌HT-1376细胞;用qRT-PCR和Western blot检测转染后TTK mRNA和蛋白的表达情况;应用CCK法和EdU方法检测细胞增殖活性;流式细胞术检测细胞周期分布及凋亡情况;transwell小室法检测细胞侵袭、迁移能力。结果显示:TTK mRNA和蛋白在癌旁正常组织、非肌层浸润性膀胱癌组织、肌层浸润性膀胱癌组织中的表达水平逐渐升高,3者之间差异有统计学意义(P0.05);过表达TTK后,HT-1376细胞增殖能力增强,细胞凋亡减少,细胞体外侵袭和迁移能力增强;而敲除TTK后,HT-1376细胞生长受抑制,细胞周期阻滞在G_0/G_1期,细胞凋亡率增加,细胞体外侵袭和迁移能力减弱。该研究结果提示,TTK的表达与膀胱癌的发生、发展有关;TTK能促进膀胱癌HT-1376细胞的增殖、侵袭、迁移,并抑制细胞凋亡。     

Notch受体在胰腺癌组织中的表达及其临床意义

目的:探讨胰腺癌及癌旁组织中Notch1～4蛋白和mRNA表达及临床意义。方法:应用免疫组化方法检测40例胰腺癌组织及对应的癌旁组织石蜡标本中Notch1～4蛋白的表达情况;分析Notch1～4受体表达水平与胰腺癌临床病理特征关系;应用实时逆转录聚合酶链反应(Real-time RT PCR)检测冰冻胰腺癌组织及对应的癌旁组织手术标本中Notch1～4的mRNA表达情况。结果:免疫组化结果显示:Notch1、Notch2在胰腺癌组织中蛋白表达明显比胰腺癌旁组织低(P0.05);Notch3在胰腺癌组织中蛋白表达比胰腺癌旁组织高,但是差异无统计学意义(P0.05);Notch4在胰腺癌组织中蛋白表达比胰腺癌旁组织高(P0.05)。Notch1～4受体的表达与肿瘤分化程度和临床分期呈负相关(P0.05)。Real-time RT PCR结果显示:与胰腺癌旁组织相比,癌组织中Notch1,Notch2的mRNA相对表达水平显著下调;胰腺癌癌组织中Notch3,Notch4的mRNA相对表达水平显著上调。结论:Notch家族的Notch1～4受体在胰腺癌组织及其旁组织的蛋白和mRNA表达不同,Notch蛋白表达可以作为胰腺癌的风险预测因子。     

mir-615-5p 通过靶向调节癌基因TRAF4抑制非小细胞肺癌细胞的增殖

已知mir-615-5p可抑制癌细胞的增殖,然而其具体分子机制尚不明确。本研究证明,mir-615-5p通过负调节癌基因TRAF4,从而抑制NSCLC细胞的增殖。运用实时定量PCR检测NSCLC患者癌组织和癌旁正常组织、正常人肺支气管上皮细胞系HBE和3种人源NSCLC细胞系中mir-615-5p的表达,发现与正常的组织和细胞相比,mir-615-5p在NSCLC癌组织和癌细胞中表达水平显著降低;运用Western印迹检测HBE细胞和NSCLC细胞系中TRAF4蛋白的表达,发现TRAF4在NSCLC细胞中表达显著升高;MTT和CCK 8分析结果显示,转染mir-615-5p mimic 可显著降低NSCLC细胞的增殖能力;生物学信息分析和萤光素酶报告基因检测结果显示,mir-615-5p可靶定结合TRAF4 mRNA,并下调TRAF4蛋白的水平;pcDNA-TRAF4转染后细胞增殖检测结果显示,过表达TRAF4能够消除mir-615-5p引起的细胞增殖抑制作用。综上所述,mir-615-5p通过靶定结合癌基因TRAF4的mRNA,下调TRAF4蛋白的水平,从而抑制NSCLC细胞的增殖。     

LATS1在食管鳞癌中的表达及启动子甲基化状态研究

在我们以前的研究中,在食管鳞癌细胞株中过表达大肿瘤抑制基因-1(large tumor suppressor kinase 1,LATS1)能够明显抑制细胞增殖、细胞迁移和侵袭,同时能够促进细胞凋亡。为了进一步研究LATS1基因在食管鳞状细胞癌发生发展中的作用以及可能的机制,我们在食管鳞癌组织与配对癌旁组织中,应用免疫组化检测LATS1基因蛋白质表达情况,应用荧光定量PCR(qRT-PCR)检测配对组织LATS1基因mRNA表达差异。甲基化特异性PCR(MSP)和亚硫酸氢盐测序法(BGS)检测食管鳞癌组织及细胞中LATS1基因的CpG岛甲基化状态。我们发现LATS1基因在癌旁组织中广泛表达,而癌组织中LATS1基因表达明显下调。结果表明LATS1在食管鳞癌中起到抑癌基因的作用,并且与肿瘤的临床分期相关,而其下调与CpG岛的高甲基化无关。在食管鳞癌细胞中过表达LATS1抑制细胞增殖、细胞迁移和侵袭,同时能够促进细胞凋亡。因此,LATS1基因值得进一步探索作为食管鳞癌生物标志物的可能用途和未来分子诊断和治疗的目标。     

干扰素诱导基因IFIT3对膀胱癌细胞生物学功能及化疗耐药性的影响

摘要 目的：探讨干扰素诱导基因IFIT3在膀胱癌中的表达及对膀胱癌细胞生物学功能和化疗耐药性的影响。方法：本研究通过qRT-PCR或Western blot检测了30例膀胱移行细胞癌患者的肿瘤组织和配对正常癌旁组织标本以及人膀胱癌细胞系T24及人膀胱上皮永生化细胞SV-HUC-1中IFIT3的表达水平。通过浓度递增法构建顺铂（DDP）耐药T24细胞（T24/DDP）,然后对细胞转染靶向IFIT3的siRNA（si-IFIT3）及阴性对照（si-NC）。将细胞分为4组,分别为T24-si-NC组、T24-si-IFIT3组、T24/DDP-si-NC组、T24/DDP-si-IFIT3组,通过MTT法检测细胞增殖,使用Annexin V-FITC/PI凋亡检测试剂盒检测细胞凋亡,使用Transwell法检测细胞侵袭能力。通过qRT-PCR或Western blot检测HSP90α（HSP90AA1）、MMP2、MMP9、Cleaved-caspase-3、Bcl-2和Bax的表达水平。结果：与配对癌旁组织和SV-HUC-1相比,膀胱癌组织和T24细胞中IFIT3的mRNA和蛋白表达水平显著升高（P<0.001）。与正常T24细胞相比,T24/DDP细胞中的IFIT3 mRNA和蛋白表达水平显著升高（P<0.001）。与T24/DDP-si-NC组相比,T24/DDP-si-IFIT3组的IC₅₀值和侵袭细胞数显著降低,而细胞凋亡率显著升高（P<0.05）。与T24/DDP-si-NC组相比,T24/DDP-si-IFIT3组的Bcl-2、MMP2和MMP9蛋白相对表达量显著降低,而Bax和Cleaved-caspase-3蛋白相对表达量显著升高（P<0.05）。String数据库显示,IFIT3与HSP90AA1基因存在互作关系。与T24/DDP-si-NC组相比,T24/DDP-si-IFIT3组的HSP90α（HSP90AA1）表达水平显著降低（P<0.05）。结论：下调IFIT3的表达可抑制膀胱癌细胞的增殖和侵袭,并促进细胞凋亡,下调IFIT3可部分通过抑制HSP90α （HSP90AA1）的表达来降低膀胱癌细胞对顺铂的耐药性。     

Overexpression of HDAC1 induces cellular senescence by Sp1/PP2A/pRb pathway

Senescence is associated with decreased activities of DNA replication, protein synthesis, and cellular division, which can result in deterioration of cellular functions. Herein, we report that the growth and division of tumor cells were significantly repressed by overexpression of histone deacetylase (HDAC) 1 with the Tet-off induced system or transient transfection. In addition, HDAC1 overexpression led to senescence through both an accumulation of hypophosphorylated active retinoblastoma protein (pRb) and an increase in the protein level of protein phosphatase 2A catalytic subunit (PP2Ac). HDAC1 overexpression also increased the level of Sp1 deacetylation and elevated the interaction between Sp1 and p300, and subsequently that Sp1/p300 complex bound to the promoter of PP2Ac, thus leading to induction of PP2Ac expression. Similar results were obtained in the HDAC1-Tet-off stable clone. Taken together, these results indicate that HDAC1 overexpression restrained cell proliferation and induced premature senescence in cervical cancer cells through a novel Sp1/PP2A/pRb pathway.     

蛋白磷酸酶4在人肺癌细胞A549增殖中的功能分析

蛋白磷酸酶4(PP4)是PP2A亚家族的重要成员之一.已有研究表明PP4在果蝇与线虫中参与了中心体成熟,但作为一个进化上高度保守的蛋白质,PP4在哺乳动物细胞中的确切功能至今仍知之甚少.选择人肺癌细胞A549为材料,转染发夹型siRNA表达质粒,筛选鉴定获得了PP4表达抑制细胞株,然后对细胞的形态、生长特性及有丝分裂过程进行观察分析.与对照细胞相比,发现其生长速率明显减慢,细胞群体中DNA含量为4N的细胞比率明显增高.这一结果是由细胞群体中出现了高比例的多核细胞造成的,进一步的分析揭示,高比例多核细胞的产生是由于PP4表达下降,致使细胞有丝分裂和胞质分裂受到严重干扰所导致的.由此推测PP4对于保证细胞有丝分裂及胞质分裂的正常进行具有重要作用,PP4受到抑制将会导致多核细胞的产生,进而抑制A549细胞的增殖.     

PP2A通过Akt/Skp2通路调控p27~(Kip1)的表达并抑制肺癌细胞的致瘤能力

蛋白磷酸酶2A(PP2A)是由36 k Da的催化亚基C(PP2Ac)和65 k Da的结构亚基A(PP2Aα/β)一起组成PP2A的核心酶,并且和各种不同的调节亚基B形成具有不同功能的PP2A全酶复合体。在细胞中PP2A发挥着重要作用,特别是在抑制肿瘤的形成当中,编码PP2Aα/β基因的突变将导致肿瘤的形成和其他疾病。当非小细胞肺癌细胞H1299中过表达PP2A-Aα时,细胞生长被抑制,细胞周期停留在G0/G1期,致瘤能力也同时被抑制。进一步研究证明当PP2A-Aα过表达时,Akt被去磷酸化失活使Skp2的表达下调,从而导致细胞周期抑制因子p27kip1的表达上调。肿瘤细胞软琼脂克隆形成实验的结果表明过表达PP2A-Aα之后H1299细胞的锚定非依赖性生长能力明显的降低,形成的克隆细胞团也较小,这些结果和裸鼠成瘤实验的结果是一致的。     

miR‐222 attenuates cisplatin‐induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells

Increased miR‐222 levels are associated with a poor prognosis in patients with bladder cancer. However, the role of miR‐222 remains unclear. In the present study, we found that miR‐222 enhanced the proliferation of both the T24 and the 5637 bladder cancer cell lines. Overexpression of miR‐222 attenuated cisplatin‐induced cell death in bladder cancer cells. miR‐222 activated the Akt/mTOR pathway and inhibited cisplatin‐induced autophagy in bladder cancer cells by directly targeting protein phosphatase 2A subunit B (PPP2R2A). Blocking the activation of Akt with LY294002 or mTOR with rapamycin significantly prevented miR‐222‐induced proliferation and restored the sensitivity of bladder cancer cells to cisplatin. These findings demonstrate that miR‐222 modulates the PPP2R2A/Akt/mTOR axis and thus plays a critical role in regulating proliferation and chemotherapeutic drug resistance. Therefore, miR‐222 may be a novel therapeutic target for bladder cancer.     

A type 2A protein phosphatase dephosphorylates the elongation factor 2 and is stimulated by the phorbol ester TPA in mouse epidermis in vivo

Mouse epidermal cytosol contains a protein phosphatase with Mr 38,000, which dephosphorylates the elongation factor 2 (EF-2) of protein biosynthesis and is stimulated after topical application of TPA to mouse skin [(1988) Biochem. Biophys. Res. Commun. 153, 1129-1135]. Dephosphorylation of EF-2 by this phosphatase is inhibited by okadaic acid at concentrations as low as 10(-8) M, but not by heparin up to concentrations of 600.micrograms/ml. The catalytic subunit of protein phosphatase 2A (PP2Ac) with EF-2 as a substrate exhibits the same sensitivity towards okadaic acid and insensitivity towards heparin as the EF-2 phosphatase of epidermal cytosol. The catalytic subunit of protein phosphatase 1 (PP1c) is strongly suppressed by heparin and less sensitive towards okadaic acid than PP2Ac. PP2Ac is around 50 times more efficient in dephosphorylating EF-2 than PP1c. These data indicate that the TPA-stimulated EF-2 phosphatase in epidermal cytosol is a type 2A protein phosphatase.     

Identification and characterization of an alternatively spliced isoform of the human protein phosphatase 2Aα catalytic subunit

PP2A is the main serine/threonine-specific phosphatase in animal cells. The active phosphatase has been described as a holoenzyme consisting of a catalytic, a scaffolding, and a variable regulatory subunit, all encoded by multiple genes, allowing for the assembly of more than 70 different holoenzymes. The catalytic subunit can also interact with α4, TIPRL (TIP41, TOR signaling pathway regulator-like), the methyl-transferase LCMT-1, and the methyl-esterase PME-1. Here, we report that the gene encoding the catalytic subunit PP2Acα can generate two mRNA types, the standard mRNA and a shorter isoform, lacking exon 5, which we termed PP2Acα2. Higher levels of the PP2Acα2 mRNA, equivalent to the level of the longer PP2Acα mRNA, were detected in peripheral blood mononuclear cells that were left to rest for 24 h. After this time, the peripheral blood mononuclear cells are still viable and the PP2Acα2 mRNA decreases soon after they are transferred to culture medium, showing that generation of the shorter isoform depends on the incubation conditions. FLAG-tagged PP2Acα2 expressed in HEK293 is catalytically inactive. It displays a specific interaction profile with enhanced binding to the α4 regulatory subunit, but no binding to the scaffolding subunit and PME-1. Consistently, α4 out-competes PME-1 and LCMT-1 for binding to both PP2Acα isoforms in pulldown assays. Together with molecular modeling studies, this suggests that all three regulators share a common binding surface on the catalytic subunit. Our findings add important new insights into the complex mechanisms of PP2A regulation.     

Purine Nucleotide- and Sugar Phosphate-Induced Inhibition of the Carboxyl Methylation and Catalysis of Protein Phosphatase-2A in Insulin-Secreting Cells: Protection by Divalent Cations

Recently, we demonstrated that the 36 kDa catalytic subunit of protein phosphatase 2A (PP2Ac) undergoes methylation at its C-terminal leucine in normal rat islets, human islets and isolated cells; this modification increases the catalytic activity of PP2A [Kowluru et al. Endocrinology. 137:2315–2323, 1996]. Previous studies have suggested that adenine and guanine nucleotides or glycolytic intermediates [which are critical mediators in cell function] also modulate phosphatase activity in the pancreatic cell. Therefore, we examined whether these phosphorylated molecules specifically regulate the carboxyl methylation and the catalytic activity of PP2A in cells. Micromolar concentrations of ATP, ADP, GTP or GDP each inhibited the carboxyl methylation of PP2Ac and, to a lesser degree, the catalytic activity of PP2A. Likewise, the carboxyl methylation of PP2Ac and its catalytic activity were inhibited by [mono- or di-] phosphates of glucose or fructose. Additionally, however, the carboxyl methylation of PP2Ac was significantly stimulated by divalent metal ions (Mn²⁺ > Mg²⁺ > Ca²⁺ > control). The nucleotide or sugar phosphate-mediated inhibition of carboxyl methylation of PP2Ac and the catalytic activity of PP2A were completely prevented by Mn²⁺ or Mg²⁺. These data indicate that divalent metal ions protect against the inhibition by purine nucleotides or sugar phosphates of the carboxyl methylation of PP2Ac perhaps permitting PP2A to function under physiologic conditions. Therefore, these data warrant caution in interpretation of extant data on the regulation of phosphatase function by purine nucleotides.     

lncRNA MIR503HG functioned as a tumor suppressor and inhibited cell proliferation,metastasis and epithelial-mesenchymal transition in bladder cancer

Bladder cancer is the most common malignancy with high recurrence. Currently, the long noncoding RNAs (lncRNAs) have been suggested to play vital roles in the pathogenesis of bladder cancer. The present study investigated the role of lncRNA MIR503 host gene (MIR503HG) in the pathogenesis of bladder cancer by using both in vitro and in vivo functional assays. The expression of MIR503HG was downregulated in bladder cancer tissues and cell lines. Low expression of MIR503HG was associated with advanced tumor stage, advanced histological grade, and lymph node metastasis. Ectopic expression of MIR503HG inhibited cell proliferation, cell growth, cell invasion, and migration, and also promoted cell apoptosis and inhibited cell cycle progression in SW780 cells. In parallel, T24 cells were used for loss-of-function studies. Knockdown of MIR503HG promoted the cancer cell proliferation and increased the migration and invasion abilities of T24 cells. In addition, knockdown of MIR503HG reduced the cell apoptotic rate in cancer cells and promoted cell cycle progression. Furthermore, MIR503HG overexpression decreased the epithelial-mesenchymal transition-related mRNA and protein levels of ZEB1, Snail, N-cadherin, and vimentin, with an increase in E-cadherin level. Consistently, knockdown of MIR503HG showed the opposite effects. In vivo xenograft, nude mice results showed that overexpression of MIR503HG suppressed the tumor growth and tumor metastasis. In conclusion, our results identified a novel lncRNA MIR503HG that exhibited significant antiproliferation, antimigration/invasion effects on bladder cancer cells both in vitro and in vivo, which may hold a therapeutic promise to treat bladder cancer.